Technology

Hoag Names Dr. Jack Sun as Director of Cardiovascular Surgery

Published

12 months ago

May 6, 2025

Nationally recognized expert in complex cardiac surgery to lead Hoag Cardiovascular Surgery ProgramDr. Sun to spearhead advanced heart failure initiativeHarvard-trained surgeon aims to redefine cardiac care at Hoag

NEWPORT BEACH, Calif., May 6, 2025 /PRNewswire/ — Jack Sun, M.D., B.S., M.S., F.R.C.S.C., has been appointed to lead the Cardiovascular Surgery Program at Hoag’s Jeffrey M. Carlton Heart & Vascular Institute, bringing with him a bold vision to position Hoag as a premier destination for advanced heart failure care.

In this role, Dr. Sun will lead the development of a comprehensive program dedicated to treating patients with the most advanced and challenging forms of heart failure. The initiative will offer cutting-edge therapies and mechanical support technologies for those whose hearts are no longer functioning effectively — including people recovering from major heart attacks or cardiac arrest.

“Dr. Sun’s arrival marks a new chapter for cardiac care at Hoag,” said Robert T. Braithwaite, Hoag President and CEO. “At Hoag, we are never satisfied with the status quo and continually strive to raise the bar for our patients. Dr. Sun’s dedication to clinical excellence and his forward-looking vision will ensure that Hoag continues to deliver the highest level of cardiac care to our community — so ultimately no patient needs to leave Orange County for the most complex heart treatment.”

A leader in the field of minimally invasive surgery, Dr. Sun brings a wealth of experience in complex cardiac procedures, including mitral valve repair, aortic surgery, surgical treatment of atrial fibrillation, and mechanical circulatory support. As part of Hoag’s renowned cardiovascular team, Dr. Sun is committed to advancing minimally invasive approaches that promote faster recovery, less pain and smaller incisions for patients — while building high-quality, patient-centered programs.

Dr. Sun previously served as Chief of Cardiac Surgery and Health Sciences Associate Clinical Professor of Surgery at the University of California, Irvine, where he spent more than six years.

He has authored or co-authored more than 60 publications, presentations and book chapters in leading medical and cardiology journals, including national guidelines. His research has earned more than $1 million in funding from the National Institutes of Health (NIH), peer-reviewed agencies, and industry sponsors.

Dr. Sun was drawn to Hoag’s commitment to excellence in cardiac care and the hospital’s dedication to patient-centric innovation.

“Hoag is well regarded for delivering world-class surgical expertise,” he said. “I have always been driven by the ability to care for patients, especially those with complex cardiac needs. I am excited to join Hoag and build upon its strong foundation to create a program that establishes a new paradigm of cardiac care.”

Dr. Sun earned his medical degree from the University of Toronto and finished residency training in cardiac surgery at McMaster University, a Canadian institution renowned for research and innovation. He completed an advanced fellowship in cardiac surgery at the Harvard University-affiliated Brigham and Women’s Hospital.

Dr. Sun’s arrival builds upon Hoag’s strong foundation in cardiovascular care. U.S. News & World Report ranked Hoag as high performing in five cardiac specialties in 2024-2025: aortic valve surgery, heart bypass surgery, heart attack and heart failure. Additionally, Hoag’s Jeffrey M. Carlton Heart & Vascular Institute was the top cardiothoracic program in Orange County in 2024, performing more than 440 cases.

Philanthropy has played a pivotal role in advancing Hoag’s cardiac and vascular programs, enabling the introduction of groundbreaking devices and procedures that are improving patient outcomes and enhancing quality of life.

“Hoag is Orange County’s hospital,” Dr. Sun said. “When patients come here, they know they will receive the highest level of care from a dedicated, collaborative team. I look forward to helping elevate that care and experience even further.”

ABOUT HOAG

Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 17 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and five ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® with Distinction hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoag-names-dr-jack-sun-as-director-of-cardiovascular-surgery-302447703.html

SOURCE Hoag

Technology

MATSON ANNOUNCES ADDITION OF 3 MILLION SHARES TO EXISTING SHARE REPURCHASE PROGRAM AND QUARTERLY DIVIDEND OF $0.36 PER SHARE

Published

1 hour ago

April 23, 2026

HONOLULU, April 23, 2026 /PRNewswire/ — The Board of Directors of Matson, Inc. (NYSE: MATX), a leading U.S. carrier in the Pacific, approved adding three million shares to its existing share repurchase program and extending the program to December 31, 2029. As of April 23, 2026, the existing share repurchase program had approximately 0.7 million shares remaining. The Board also declared a second quarter dividend of $0.36 per common share. The dividend will be paid on June 4, 2026 to all shareholders of record as of the close of business on May 7, 2026.

“We are pleased to announce an additional three million shares to our existing share repurchase program,” said Matt Cox, Matson’s Chairman and Chief Executive Officer. “Since we commenced our share repurchase program in August 2021, we have repurchased approximately 14.3 million shares, or approximately 33% of the then outstanding shares, for a total cost of $1.3 billion. Going forward, we will continue to be both disciplined and opportunistic in our capital allocation, and we remain committed to returning excess cash to shareholders to create additional shareholder value over the long-term.”

Shares will be repurchased in the open market from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its common shares and general market conditions. The Company may enter into Rule 10b5-1 plans to facilitate purchases under the program. The repurchase program may be suspended or discontinued at any time.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services. Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia. Matson also operates premium, expedited services from China to Long Beach, California, which includes cargo from other Asia origins, provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia. The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges. Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia. Its integrated logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska. Additional information about the Company is available at www.matson.com.

Forward Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to, statements about capital allocation plans, the timing, manner and volume of repurchases of common shares pursuant to the repurchase program, and use of excess cash. These forward-looking statements are not guarantees of future performance. This release should be read in conjunction with our Annual Report on Form 10-K and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release. We do not undertake any obligation to update our forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-addition-of-3-million-shares-to-existing-share-repurchase-program-and-quarterly-dividend-of-0-36-per-share-302752377.html

SOURCE Matson, Inc.

Technology

Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards

Published

2 hours ago

April 23, 2026

ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients across multiple states, has been named a finalist in the MMIT Patient Choice Awards, a recognition based on patient-reported satisfaction and experience.

Accord was selected as the only independent pharmacy among finalists in its category, alongside national pharmacy organizations such as Walgreens Specialty Pharmacy and Walmart Specialty Pharmacy. This distinction highlights the company’s commitment to delivering personalized, high-touch care for patients managing complex and chronic conditions.

The MMIT Patient Choice Awards recognize specialty pharmacies that demonstrate excellence in patient satisfaction, service quality, and overall care experience. Finalists are determined based on direct patient feedback, making the recognition a meaningful reflection of the trust patients place in their pharmacy providers.

“Being recognized alongside national organizations and as the only independent finalist validates our belief that personalized, patient-centered care drives better outcomes. We are building a model that combines clinical depth, national reach, and operational flexibility to better serve patients, providers, and partners.” said AJ Patel, Founder and Pharmacy Manager of Accord Specialty Pharmacy.

Accord Specialty Pharmacy supports patients across complex specialty categories, including oncology, rare disease, and infusion, through a clinically driven, high-touch care model designed to improve access, adherence, and outcomes. The company’s approach emphasizes personalized support, responsive care coordination, and strong clinical engagement to help patients navigate complex therapies more effectively. With a growing national footprint and multi-state licensure, Accord is positioned to support patients, providers, and partners across diverse markets.

For more information, visit MMIT Announces Finalists of the 11th Specialty Pharmacy Patient Choice Awards – MMITNetwork.

About Accord Specialty Pharmacy:

Accord Specialty Pharmacy is an ACHC-accredited, multi-state licensed independent specialty pharmacy located in Central Florida, dedicated to delivering high-quality, patient-centered care for individuals managing complex and chronic conditions. Through personalized support, clinical expertise, and a high-touch approach, Accord helps patients navigate every step of their treatment journey. Learn more at www.accordspecialty.com.

CONTACT: contact@accordspecialty.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-specialty-pharmacy-named-finalist-in-mmits-11th-annual-retail-specialty-pharmacy-patient-choice-awards-302752327.html

SOURCE Accord Specialty

Technology

HAIVISION ANNOUNCES VOTING RESULTS FROM 2026 ANNUAL MEETING OF SHAREHOLDERS

Published

2 hours ago

April 23, 2026

MONTRÉAL, April 23, 2026 /CNW/ – Haivision Systems Inc. (“Haivision” or the “Company”) (TSX: HAI) is pleased to announce the voting results from its annual meeting of shareholders held today in a virtual format.

A total of approximately 45.97 % of the issued and outstanding common shares of Haivision were represented at the meeting.

Election of Directors

Each of the six nominated directors of Haivision was elected as director of the Company with the following results:

Director

Votes
For

% Votes
For

Votes
Against

% Votes
Against

Miroslav Wicha

11,110,245

99.26 %

82,583

0.74 %

Harvey Bienenstock

11,155,137

99.66 %

37,691

0.34 %

Robin M. Rush

11,121,855

99.37 %

70,973

0.63 %

Neil Hindle

10,794,005

96.44 %

398,823

3.56 %

Julie Tremblay

10,941,969

97.76 %

250,859

2.24 %

Lee K. Levy II

9,084,418

81.16 %

2,108,410

18.84 %

2. Appointment of Auditors

Deloitte LLP were reappointed auditors of the Company for the ensuing year with 12,492,582 (98.84%) votes cast in favour and 146,406 (1.16%) votes withheld.

3. Approval of the Unallocated Awards under the Company’s Equity Incentive Plan

The Company’s unallocated awards were approved with 8,710,347 (77.82%) votes cast in favour and 2,482,481 (22.18%) votes cast against.

4. Reapproval of Company’s Shareholder Rights Plan

The Company’s shareholder rights plan was approved with 10,572,490 (94.46%) votes cast in favour and 620,338 (5.54%) votes cast against.

Final voting results on all matters voted on at the meeting will be filed under Haivision’s profile on SEDAR+ at www.sedarplus.ca.

About Haivision

Haivision is a leading global provider of mission-critical, real-time video streaming and visual collaboration solutions. Our connected cloud and intelligent edge technologies enable organizations globally to engage audiences, enhance collaboration, and support decision making. We provide high quality, low latency, secure, and reliable live video at a global scale. Haivision open sourced its award-winning SRT low latency video streaming protocol and founded the SRT Alliance to support its adoption. Awarded four Emmys® for Technology and Engineering from the National Academy of Television Arts and Sciences, Haivision continues to fuel the future of IP video transformation. Founded in 2004, Haivision is headquartered in Montreal and Chicago with offices, sales, and support located throughout the Americas, Europe, and Asia. Learn more at haivision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/haivision-announces-voting-results-from-2026-annual-meeting-of-shareholders-302752318.html

SOURCE Haivision Systems Inc.